Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This placebo-controlled study is designed to evaluate the efficacy of glycine, an agonist of
the glycine-B co-agonist site of the NMDA receptor, on alcohol consumption and craving as
well as negative symptoms in schizophrenia.
Glycine will decrease the rewarding action of ethanol and reduce ethanol consumption. Also,
glycine will improve negative symptoms and cognitive deficits in schizophrenia.